For two decades, breadth was the proof of seriousness in spine. A catalogue that answered any anatomy, any approach and any surgeon preference was how you earned the right to be in the room. Nobody in this industry ever got promoted for killing a screw size. Portfolio rationalization is arriving in spine anyway, and it is arriving through the balance sheet rather than through strategy decks.
The long tail is not just inertia. It is protected by both commercial relationships and contracting structures. Spine is sold surgeon by surgeon, and in the U.S. the relationship frequently belongs to an independent distributor rather than to the manufacturer. Killing a slow-moving reference is not a catalogue decision; it is a conversation in which somebody’s bag gets smaller and the cases may walk. On the other side, IDN and GPO agreements often reward full-line coverage, so the same reference that loses money in the warehouse earns its keep in a contract. VB Spine says it offers more than 20,000 spinal products, by the company’s own count, and that is a focused business by the standards of this market.
The pressure is real, but the reflex it produces is the wrong one. Reducing the catalogue is not the same as emptying the tray, though the two get confused deliberately. The surgeon rarely comes up short because the company carries 12,000 references instead of 20,000. The shortfall happens because somebody optimised the tray on rotation alone, and the extremes always fall first — the longest screw, the highest-lordosis cage, the size used twice a year. Those are precisely the references with no substitute in the room. The cost of carrying them is small and known. The cost of their absence is a compromised construct and a surgeon who stops calling. One of those numbers sits in a spreadsheet and the other sits nowhere, which is how tray decisions get made in operations and discovered in theatre six months later.
Nothing about that makes the tail affordable. What has changed is the cost of sustaining it. Manufacturing the implant is the cheapest part. Each reference drags inventory and consignment, instruments, trays, storage, logistics, sterilisation, documentation, UDI and traceability, complaint handling and post-market surveillance, plus a regulatory file that must be maintained whether it sells 5,000 units or five.
Europe has turned that overhead into a number. MedTech Europe models average MDR maintenance of roughly €99,648 per device per year, with about 90% of first-year certification cost going to personnel, and expects maintenance and re-certification to exceed initial certification over a five-year cycle. For a marginal reference, that is a recurring cost with no plausible return. It is also why 54% of respondents to the 2022 survey said they would not transition part of their portfolio, those planning cuts expecting to drop an average of 33% of their devices. China applies the pressure from the other direction: the 2022 national tender for spinal products cut prices by an average of 84%, and tendered markets do not pay for breadth.
The clearest arithmetic so far comes from orthopaedics. Smith+Nephew entered its 12-Point Plan with 128 major orthopaedic product families, identified 19 for phase-out, added roughly 50 more in late 2025, predominantly in trauma, and expects to land at 59 families, a 54% reduction, over three to five years. The prize is around $500 million of gross inventory. The entry ticket was a $159 million non-cash obsolescence provision. Spine people will object that knees and hips are not spine, and they are right: in recon the tail sits in product families, in spine it sits in the bag. But the sequence travels. You pay for the purge before you collect on it.
Spine’s own version has mostly arrived disguised as exits. Orthofix discontinued the M6-C and M6-L, $23.4 million of 2024 sales, in a move it said reflected strategy rather than clinical performance, while still owing post-market surveillance and a U.S. IDE study. Stryker sold its U.S. spine implant business outright; J&J intends to separate Orthopaedics. Globus has actioned $200 million of NuVasive synergies against a $170 million target, though those are cost synergies across manufacturing and footprint rather than a declared SKU purge. Meanwhile the market leader is doing something else entirely: Medtronic is making the ecosystem the differentiator, with core spine up 8% in recent quarters on pull-through from its enabling-technology platform, not on catalogue depth.
Growth does not exempt anyone either. ATEC generated $34 million of operating cash flow in Q2 2026 and put $33 million straight back into inventory and instrument sets, leaving about $1 million of free cash flow.
That puts the question back on criteria rather than volume. Nobody publishes how many references sell in single digits, and anyone quoting such a figure is guessing. So measure your own: revenue per reference over twelve months; sets deployed per case; turns on consigned sets; the age of the oldest consignment sitting in each account; and fully loaded regulatory cost per reference, by market. Then cut on rotation and substitutability, never rotation alone, and move the clinical tail into central banks and modular constructs instead of leaving it consigned everywhere and calling it coverage. Most companies cannot produce those five numbers quickly.
Which is the real design brief: modular constructs, shared instrumentation, fewer trays per procedure, systems that stretch across approaches instead of one system per approach. The next competitive advantage in spine may not be having more implants, but covering more procedures with fewer platforms.
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.